For example, we recently showed that subcutaneous co-delivery of the STING pathway agonist cyclic di-AMP (CDA) synergized with ECM scaffold delivery in a therapeutic cancer vaccine while maintaining Type 2 immune signatures like IL-4 expression and STAT6 phosphorylation8. This evidence concerns the gene STING1 and cancer.